Pharmacological treatment of Alzheimer disease: From psychotropic drugs and cholinesterase inhibitors to pharmacogenomics

Drugs of Today

Volumn 36, Issue 7, 2000, Pages 415-499

  Cacabelos, R ^a   Alvarez, A ^a   Lombardi, V ^a   Fernandez Novoa, L ^a   Corzo, L ^a   Perez, P ^a   Laredo, M ^a   Pichel, V ^a   Hernandez, A ^a   Varela, M ^a   Figueroa, J ^a   Prous J , Jr ^a   Windisch, M ^a   Vigo, C ^a  

^a Centro de Investigacion Biomedica EuroEspes   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 (BENZO[B]THIEN 5 YL) 2 (2 DIETHYLAMINOETHOXY)ETHANOL; 10,10 BIS(2 FLUORO 4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; 2 (2 OXO 1 PYRROLIDINYL) N (5,6,7,8 TETRAHYDRO 2,3 DIMETHYLFURO[2,3 B]QUINOLIN 4 YL)ACETAMIDE; 3,6,7,9 TETRAHYDRO 2 (3 ISOXAZOLYL)IMIDAZO[4,5 D]PYRANO[4,3 B]PYRIDINE; 4 [[2 (1 METHYL 2 PYRROLIDINYL)ETHYL]THIO]PHENOL; AMIRIDINE; ANSECULIN; ANTIINFLAMMATORY AGENT; CELECOXIB; CEREBROLYSIN; CHOLINESTERASE INHIBITOR; DONEPEZIL; ERANZ; GALANTAMINE; IPENOXAZONE; MEMANTINE; MUSCARINIC AGENT; N (4 ACETYL 1 PIPERAZINYL) 4 FLUOROBENZAMIDE; NEBRACETAM; NEFIRACETAM; NICOTINIC AGENT; NOOTROPIC AGENT; PSYCHOTROPIC AGENT; REMENYL; RIVASTIGMINE; ROFECOXIB; SABCOMELINE; SABELUZOLE; TACRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZANEPEZIL;

ALZHEIMER DISEASE; CELL TRANSPLANTATION; CLINICAL TRIAL; COGNITIVE THERAPY; GENE THERAPY; HORMONE SUBSTITUTION; HUMAN; INSOMNIA; PALLIATIVE THERAPY; PARKINSONISM; PHARMACOGENOMICS; REVIEW; SUBSTITUTION THERAPY;

EID: 0033850870     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (428)

1. Use of THA in treatment of Alzheimer-like dementia: Pilot study in twelve patients
2. Tacrine: First generation of antidementia drugs
3. Molecular strategies for the first generations of anti-dementia drugs (I). Tacrine and related disorders
4. Dementia
5. Pharmacoeconomic aspects of Alzheimer's disease and its treatment
6. Treatment of Alzheimer disease with tacrine: A cost-analysis model
7. Tacrine for Alzheimer's disease: Costs and benefits
8. The potential impact of tacrine on expenditures for Alzheimer's disease
9. The economic consequences of Alzheimer's disease in the context of new drug developments
10. The economic impact of tacrine in the treatment of Alzheimer disease
11. Caregivers perception on dementia-associated social, economic and health problems: Socioeconomic study in the Spanish population
12. The glutamatergic system and neurodegeneration in dementia: Preventive strategies in Alzheimer's disease
13. Alzheimer's disease: Pharmacoeconomics, glutamate-induced neurodegeneration and preventive strategies
14. The global burden of disease, 1990-2020
15. Genetic classification of primary degenerative disease
16. Alzheimer diseases: A model of gene mutations and susceptibility polymorphisms for complex psychiatric diseases
17. Diagnosis of Alzheimer's disease: Defining genetic profiles (genotype vs phenotype)
18. Genetic testing in Alzheimer's disease: APOE genotyping and etiopathogenic factors
19. Association of genetic risk factors and a novel mutation in the predicted TM2 domain of the presenilin 2 gene in late-onset AD
20. Genetic neurodegenerative diseases: The human illness and transgenic models
21. Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis
22. Molecular basis of the neurodegenerative disorders
23. New strategies for Alzheimer's disease treatment: Pleiotropic drugs and multifactorial intervention
24. Cerebrovascular pathology in Alzheimer's disease
25. Oxidative damage in neurodegenerative diseases
26. Are reactive oxygen species involved in Alzheimer's disease?
27. Oxidative damage in neurodegenerative disorders
28. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease
29. Modification of ion homeostasis by lipid peroxidation: Roles in neuronal degeneration and adpative plasticity
30. Advances in the management of stroke. The role of piracetam
31. Idebenone. A review of its use in mild to moderate Alzheimer's disease
32. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease
33. Anapsos: Neuroimmunotrophic treatment in Alzheimer disease and neurodegenerative disorders
34. Neurotrophicactivities and therapeutic experience with a brain derived peptide preparation
35. Propentofylline
36. Calcium channel blockade and incidence of cancer in aged populations
37. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Sys-Eur) trial
38. Prevention of dementia: Sys-Eur trial
39. Calcium antagonist and prevention of dementia in elderly people
40. + channel cascade
41. Calcium-antagonist drugs
42. P/Q-type calcium channels mediate the activity-dependent feedback of syntaxin-1A
43. Behavioral changes associated with different apolipoprotein E genotypes in dementia
44. APOE-related frequency of cognitive and noncognitive symptoms in dementia
45. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people
46. Antidepressants and the risk of falls among nursing home residents
47. Efficacy of acute treatment for geriatric depression
48. Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline
49. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia
50. Citalopram. A review of its pharmacology, clinical efficacy and tolerability in the treatment of depression
51. Tianeptine for depression in the elderly
52. The treatment of psychotic depression in later life: A comparison of pharmacotherapy and ECT
53. Drug-induced behavioural disinhibition
54. Prospects for anxiolytic therapy: A reflection from different viewpoints
55. 1(A) receptor agonists as antidepressants. Pharmacological rationale and evidence for efficacy
56. Benzodiazepine actions mediated by specific γ-aminobutyric acid(A) receptor subtypes
57. Toward better benzodiazepines
58. Mood stabilizer combinations: A review of safety and efficacy
59. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia
60. Arandomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease
61. Newer atypical antipsychotics
62. Behavioural problems associated with dementia. The role of newer antipsychotics
63. Serotonin transporter and psychiattic disorders: Listening to the gene
64. The cerebral cortex: A case for a common site of action of antipsychotics
65. Neuroleptics in progressive structural brain abnormalities in psychiatric illness
66. Drug interactions with antipsychotic agents. Incidence and therapeutic implications
67. Antihypertensive drugs can affect intellectual function
68. Serenics. Therapeutic potential in aggression
69. Melatonin as a chronobiofic drug
70. Melatonin in humans
71. The role of melatonin and serotonin in aging: Update
72. Melatonin production: Proteasomal proteolysis in serotonin N-acetyltransferase regulation
73. Antioxidant capacity of melatonin: Its defensive role against age-related diseases
74. Melatonin for the treatment of sleep disturbances in major depressive disorder
75. Melatonin receptors step into the light: Cloning and classification of subtypes
76. Does melatonin have an effect on cognitive performance?
77. Levodopa-induced neurotoxicity. Does it represent a problem for the treatment of Parkinson's disease?
78. Psychiatric adverse effects of anticonvulsant drugs. Incidence and therapeutic implications
79. Antiparkinsonian agents. Clinically significant drug interactions and adverse effects, and their management
80. Neuroimmune function of brain histamine: Implications for neurotrophic activity and neurotoxicity
81. 3 receptor agonists and antagonists
82. Growth hormone-releasing factor in mental disorders: A diagnostic marker and therapeutic alternative
83. Influence of the somatotropinergic system on mental function and psychomotor activity: Environmental factors, development, cognition, and neuropsychiatric disorders
84. Influence of somatostatin and growth hormone releasing factor on behavior. Clinical and therapeutic implications in neuropsychiatric disorders
85. A 30-week, randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
86. Safety of tacrine: Clinical trials, treatment and postmarketing experience
87. Donepezil
88. Clinical efficacy of donepezil hydrochloride in patients with Alzheimer's disease: Case studies
89. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. The Donepezil Study Group
90. A randomised trial evaluating the efficacy and safety of ENA-713, a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
91. Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's disease: An overview
92. Safety/tolerability trial of SDZ-ENA-713 in patients with probable Alzheimer's disease
93. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease
94. Eptastigmine
95. Galanthamine hydrobromide: Interim results of a group of comparative, placebo-controlled study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer type
96. Evaluation of HP-029 (velnacrine maleate) in Alzheimer's disease
97. Managing treatment expectation in Alzheimer's disease
98. Cholinesterase inhibitors for Alzheimer's disease therapy. Do they work?
99. Alzheimer's disease: From the cholinergic hypothesis to cholinergic treatment
100. Recent developments in the drug treatment of Alzheimer's disease
101. Guidelines for the appropriate use of cholinesterase inhibitors in patients with Alzheimer's disease
102. New acetylcholinesterase inhibitors
103. Guidelines for conducting bridging studies in Alzheimer disease
104. The role of bridging studies in the development of cholinesterase inhibitors for Alzheimer's disease
105. Optimizing drug development for the next generation of Alzheimer's disease compounds
106. Huperzine A: A novel acetylcholinesterase inhibitor
107. Pharmacological profile of huperzine A, a novel acetylcholinesterase inhibitor from Chinese herb
108. NXX-066 in patients with Alzheimer's disease: A bridging study
109. Cholinergic markers in elderly patients with early signs of Alzheimer disease
110. Challenging the cholinergic hypothesis in Alzheimer disease
111. The cholinesterases: From genes to proteins
112. Mapping the human acetylcholinesterase gene to chromosome 7q22 by flourecent in situ hybridization coupled with selective PCR amplication from somatic hybrid cell panel and chromosome-sorted DNA libraries
113. Molecular and cellular biology of cholinesterases
114. Selectivity of chlolinesterase inhibition. Clinical implication for the treatment of Alzheimer's disease
115. Acetylchlolinesterase and inhibitor: Effects upon normal and regenerating nervves of the rat
116. The vicious cylce of stress and antichlolinesterase responses
117. Acetylcholine in mind: A neurotransmitter correlate of consciousness?
118. Abnormal regulation of cortipetal cholinergic neurons and impaired information processing in neuropsychiatric disorders
119. Chlonergic therapies in Alzheimer's disease
120. Effects of xanomiline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease
121. The molecular basis underlying the discrete activation of signal transduction pathways by selective muscarinic agonist
122. Muscarinic modulation of β-amyloid precursor protein (APP) processing in vitro and in vivo
123. 1 muscarinic agonist: From Treatment toward delaying progression of Alzheimer's disease
124. Muscarinic receptor agonists in Alzheimer's disease
125. Milameline: Nonselective, partial muscarinic receptor agonist for the treatment of Alzheimer's disease
126. Allosteric modulators of ligand binding to muscarinic acetylcholine receptors
127. Nicotinic receptors in the brain: Correlating physiology with function
128. Nicotine: Not just for cigarettes anymore
129. Therapeutic effects of CDP-choline in Alzheimer's disease and multi-infarct dementia: Psychometric assessment and immune function
130. Effect of CDP-choline on cognition and immune function in Alzheimer's disease
131. Influence of CDP-choline on cognition and interleukin-1beta in Alzheimer's disease and multi-infarct dementia
132. Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors
133. Treatment of Alzheimer's disease with CDP-choline: Effects on mental performance, brain electrical activity, cerebrovascular parameters, and cytokine production
134. Choline, a vital amine
135. Memory-enhancing effects of citicoline in elderly nondemented people
136. Effects of citicholine on cognitive performance, brain bioelectrical activity and brain hemodynamics in Alzheimer's disease patients: A double-blind placebo controlled study
137. Citicoline antagonizes bromazepam-induced amnesia in rats
138. β-Amyloid(1-40)-induced neurodegeneration in the rat hippocampal neurons of the CA1 subfield
139. Brain mapping and transcranial Doppler ultrasonography in Alzheimer disease drug monitoring
140. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer's disease
141. CDP-choline-induced blood histamine changes in Alzheimer's disease
142. Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer's disease
143. Citicholine protects hippocampal neurons against apoptosis induced by brain β-amyloid deposits plus cerebral hypoperfusion in rats
144. Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia
145. Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine
146. Glutamate in CNS disorders
147. Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under memantine treatment
148. Protection of memantine against Aβ(1-40)-induced neurodegeneration in the CA1 subfield
149. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment
150. Glial cell reactions in dementia: Pathophysiology and therapeutic interventions
151. Brain interleukin-1β in Alzheimer's disease and vascular dementia
152. Serum tumor necrosis factor (TNF) in Alzheimer's disease and multi-infarct dementia
153. The usefulness of neurotrophic factors for treatment of Alzheimer's disease
154. Effects on the central nervous system of celastrol, a potent antioxidant and anti-inflammatory agent
155. Support of homeostatic glial cell signalling: A novel therapeutic approach by propentofylline
156. Brain-derived peptides reduce the size of cerebral infarction and loss of MAP2 immunoreactivity after focal ischemia in rats
157. Antioxidant systemic effect of short-term cerebrolysin administration
158. Cerebrolysin protects isolated cortical neurons from neurodegeneration after brief histotoxic hypoxia
159. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM-III-R
160. Clinical trials in dementia with propentofylline
161. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: A review of phase III trials
162. Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: Overview of phase I and phase II clinical trials
163. Propentofylline (HWA 285), a neuroprotective glial cell modulator: Pharmacologic profile
164. Nonsteroidal anti-inflammatory drugs and Alzheimer's disease. Update on recent data and their therapeutic implications
165. 2 blocking drugs
166. Clinical trial of indomethacin in Alzheimer's disease
167. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs
168. CNS adverse effects of nonsteroidal anti-inflammatory drugs. Therapeutic implications
169. Molecular characterization of the neuroprotective activity of salicylates
170. Cyclooxygenase 2 inhibitors: Discovery, selectivity and the future
171. Cyclooxygenase 1 and 2
172. COX-2 inhibitors
173. Inflammatory pathogenesis in Alzheimer's disease: Biological mechanisms and cognitive sequeli
174. Interleukin-1 blockers: A new class of nonarachidonate, nonsteroidal antiinflammatory drugs
175. En passant neurotrophic action of an intermediate axonal target in the developing mammalian CNS
176. Neurotrophin-evoked rapid exciration through TrkB receptors
177. Exciting neurotrophins
178. A femtomolaracting neuroprotecfive peptide
179. Sonic hedgehog protein. A novel approach to the treatment of neurodegenerative disorders?
180. 2 on short-term memory: Neuroendocrine and neuropsychological assessment in healthy young subjects
181. Age- and sex-related growth hormone (GH) levels in psychiatric patients and healthy control subjects. A correlation study between GH values and cognitive performance
182. Influence of growth hormone (GH) and GH-releasing factor on locomotor activity in rats
183. Preventive treatment of Alzheimer's disease. Peptide-mediated neuroprotection
184. Therapeutic peptides revisited
185. Proteomics: Key technology in drug discovery
186. Improving protein therapeutics with sustained-release formulations
187. Nonpeptide antagonists of neuropeptide receptors: Tools for research and therapy
188. Effect of growth-hormone therapy on early atherosclerotic changes in GH-deficient adults
189. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy
190. Increased mortality associated with growth hormone treatment in critically ill patients
191. Growth hormone therapy in critically ill patients
192. Growth hormone therapy in adults and children
193. Human growth hormone receptor: Structural characteristics, expression study and gene regulation
194. Growth-hormone and prolactin excess
195. Growth hormone secretagogues: Recent advances and applications
196. Sleep and endocrine changes after intranasal administration of growth hormone-releasing hormone in young and aged humans
197. Prolyl endopeptidase inhibitors: A new class of memory enhancing drugs
198. Effects of S-9977-2 on psychomotor activity, learning and brain interleukin-1β levels in rats
199. Neuroprotective role of S12024 against neurodegeneration in the rat dentate gyrus
200. Effects of S-12024 on brain electrical activity parameters in patients with Alzheimer's disease
201. Effects of S9977-2, a new cognition-enhancing drug, on behavior and brain neurotransmitters in rats
202. FK960 N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate ameliorates the memory deficits in rats through a novel mechanism of action
203. Proof of efficacy of the Ginkgo biloba special extract Egb 761 in out-patients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia
204. The endocrinology of aging
205. Hormone replacement therapy. Clinical Synthesis Panel on HRT
206. The menopause
207. Prescribing for seniors. Neither too much nor too little
208. Endogenous hormones and the risk of hip and vertebral fractures among older women
209. Oral contraceptive use and risk of hip fracture: A case-control study
210. Oestrogen improves exercise-induced myocardial ischaemia in women
211. Venous thromboembolism and oral contraceptives
212. Hormone replacement therapy and risk of breast cancer
213. Hormone replacement therapy and high S phase in breast cancer
214. Low-potency oestrogen and risk of endometrial cancer: A case-control study
215. Postmenopausal hormone therapy and mortality
216. Postmenopausal hormone replacement therapy and mortality
217. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives
218. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: Results of an international, multicentre, case-control study. WHO collaborative study of cardiovascular disease and steroid hormone contraception
219. Ischaemic stroke and combined oral contraceptives: Results of an international, multicentre, case-control study. WHO collaborarive study of cardiovascular disease and steroid hormone contraception
220. Hormone replacement therapy and risk of non-fatal stroke
221. Risk of idiopathic cerebral haemorrhage in women on oral contraceptives with differing progestagen components
222. Venous thromboembolism among new users of different oral contraceptives
223. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes
224. Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia
225. Oestrogen helps to protect memory into old age
226. Steroid hormones, memory and mood in a healthy elderly population
227. Sex differences and menstrual cycle effects in human spatial memory
228. Two weeks of transdermal estradiol treatment in postmenopausal elderly women and its effect on memory and mood: Verbal memory changes are associated with the treatment induced estradiol levels
229. Estradiol facilitates performance as working memory load increases
230. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks
231. Relationships of serum estradiol levels, menopausal duration, and mood during hormonal replacement therapy
232. Pregnancy, the postpartum, and steroid hormones: Effects on cognition and mood
233. The effect of hormone replacement therapy on cognitive function in elderly women
234. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease
235. Estrogen replacement therapy for the prevention and treatment of Alzheimer's disease
236. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: Results of a placebo-controlled, double-blind, pilot study
237. Estrogen reduces neuronal generation of Alzheimer β-amyloidpeptides
238. Estrogen replacement therapy and Alzheimer's disease in the Italian longitudinal study on aging
239. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore longitudinal study of aging
240. Estrogen replacement therapy and risk of Alzheimer disease
241. Cognitive skills associated with estrogen replacement therapy in women with Alzheimer's disease
242. Effects of estrogen replacment therapy on response to tacrine in patients with Alzheimer's disease
243. Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease
244. Potential role for estrogen replacement therapy in the treatment of Alzheimer's dementia
245. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: A population-based case-control study
246. Further psychometric evaluation of older women: The effect of estrogen administration
247. The effect of castration and per oral estrogen therapy on some psychological functions
248. The influence of estrogen on the psyche in climateric and post-menopausal women
249. Replacement therapy with piperazine oestrone sulfate (Harmogen) and its effects on memory
250. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women
251. In vivo effects by estrone sulfate on the central nervous system in senile dementia (Alzheimer's type)
252. Estrogen improves psychological function in asymptomatic postmenoapusal women
253. Estrogen use and verbal memory in healthy post-menopausal women
254. Oestrogen therapy and the menopausal syndrome
255. The effect of estrogen replacement therapy on cognitive function in women: A critical review of the literature
256. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia
257. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type
258. Role of estrogen replacement therapy in memory enhancement and the prevention of neuronal loss associated with Alzheimer's disease
259. Anti-inflammatory properties of estrogen: I. In vivo suppression of leukocyte production in bone marrow and redistribution of peripheral blood neutrophils
260. Neuroprotection against oxidative stress by estrogens: Structure-activity relationship
261. Effects of substitution therapy on the activity of nitrous oxide synthase
262. The female sex hormone oestrogen as a neuroprotectant
263. Estrogen hits the surface
264. New insights into the regulation and function of brain estrogen synthase (aromatase)
265. The effects of steroid hormones on electrical activity of excitable cells
266. Experimental therapeutics of neurodegenerative disorders: Unmet needs
267. Rat cell cultures: Experimental models to study neurodegenerative disorders and new pharmacological compounds
268. An experimental model to study the cytotoxic effects induced by beta-amyloid, histamine, LPS and serum from Alzheimer patients on cultured rat endothelial cells
269. 19/20 kDa low molecular weight serum protein pattern: A novel potential biochemical prognostic marker for different types of dementia
270. Microglial activation induced by factor(s) contained in sera from Alzheimer-related ApoE genotypes
271. β-Amyloid formation as a potential therapeutic target for Alzheimer's disease
272. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
273. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
274. Rationalazing a pharmacological intervention on the amyloid precursor protein metabolism
275. Curing amyloidosis: Will it work in humans?
276. Neuroprotective approaches in experimental models of β-amyloid neurotoxicity: Relevance to Alzheimer's disease
277. Amyloid disrupting drugs. Potential in the treatment of Alzheimer's disease
278. β-Sheet breaker peptides inhibit fibrillogene-sis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy
279. Matrix metalloproteinases and diseases of the CNS
280. Self-compartmentalizing proteases
281. The ubiquitin system
282. Ubiquitin, cellular inclusions and their role in neurodegeneration
283. The calpain hypothesis of neurodegeneration: Evidence for a common cytotoxic pathway
284. Potential contribution of proteases to neuronal damage
285. Inhibition of ischaemic hippocampal neuronal death in primates with cathepsin B inhibitor CA-074: A novel strategy for neuroprotection based on 'calpain-cathepsin hypothesis'
286. Tau protein mutations confirmed as neuron killers
287. Tau protein pathology in neurodegenerative diseases
288. Neuropathology of the cerebral cortex in Alzheimer's disease
289. Tau mutations cause frontotemporal dementias
290. Tau gene mutation in familial progressive subcortical gliosis
291. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17
292. Alzheimer neurofibrillary degeneration: A leasible and key target for therapeutics
293. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein
294. Alzheimer disease PS-1 exon 9 deletion defined
295. Twenty-nine missense mutations linked with familial Alzheimer's disease alter the processing of presenilin 1
296. The presenilins in Alzheimer's disease - Proteolysis holds the key
297. Presenilins, amyloid-β and Alzheimer's disease
298. The presenilins
299. Function and dysfunction of the presenilins
300. Presenilins: Molecular switches between proteolysis and signal transduction
301. Amyloid production and deposition in mutant amyloid precursor protein and presenilin-1 yeast artificial chromosome transgenic mice
302. Transgenic mice with Alzheimer presenilin-1 mutations show accelerated neurodegeneration without amyloid plaque formation
303. Alzheimer's disease-linked mutation of presenilin-2 (N141I-PS2) drastically lowers APPalpha secretion: Control by the proteasome
304. Perspectives: Neurobiology. Cranking it up a Notch
305. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity
306. Dead end for neurodegeneration?
307. Contact-dependent inhibition of cortical neurite growth mediated by Notch signaling
308. Neurogenic phenotypes and altered Notch processing in Drosophila presenilin mutants
309. Presenilin is required for activity and nuclear access of Notch in Drosophila
310. Risks seen in potential drugs for Alzheimer's disease
311. In search of γ-secretase
312. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knockin mice
313. Functional interaction of an axin homolog, conductin, with β-catenin, APC, and GSK3β
314. Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of β-catenin, a component of the presenilin protein complex
315. Oxidative stress hypothesis in Alzheimer's disease
316. Amyloid β-protein toxicity and oxidative stress in Alzheimer disease
317. Glutamate transporters are oxidant-vulnerable: A molecular link between oxidative and excitotoxic neurodegeneration?
318. Human aging brain disorders: Role of antioxidant enzymes
319. β-Amyloid neurotoxicity in vitro: Evidence of oxidative stress but not protection by antioxidants
320. Vitamin E protects against Alzheimer's amyloid peptide (25-35)-induced changes in neocortical synaptosomal membrane lipid structure and composition
321. Characteristics of the in vitro vasoactivity of β-amyloid peptides
322. Amyloid β-peptide induces cell monolayer albumin permeability, impairs glucose transport, and induces apoptosis in vascular endothelial cells
323. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein
324. Vitamin E suppresse isoprostane generation in vivo and reduces atherosclerosis, in ApoE-deficient mice
325. 2-isoprostane levels are increased in Alzheimer's disease: Evidence of increased oxidative stress in vivo
326. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease
327. Addition of vitamin E to donepezil as a treatment for Alzheimer's disease
328. Advanced glycation end product (AGE) inhibition as a possible pharmacotherapeutic strategy in the treatment of AIzheimer's disease
329. Alzheimer's disease. A glycation connection
330. High-affinity receptor-mediated uptake and degradation of glucose-modified proteins: A potential mechanism for the removal of senescent macromolecules
331. Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging
332. Advanced Maillard reaction end products are associated with Alzheimer's disease pathology
333. Advanced glycation end products contribute to amyloidosis in Alzheimer's disease
334. New hypothesis on etiopathogenesis of Alzheimer syndrome: Advanced glycation end products (AGEs)
335. Enhanced binding of advanced glycation end products (AGE) by ApoE4 isoform links the mechanism of plaque deposition in Alzheimer's disease
336. Age-dependent accumulation of advanced glycosylation end products in human neurons
337. Role of protein-bound carbonyl groups in the formation of advanced glycation end products
338. Fetal transplantation for the treatment of neurodegenerative diseases. Current status and future potential
339. Restoring production of hippocampal neurons in old age
340. New neurons in old brains: Learning to survive
341. Chimeric brains generated by intraventricular transplantation of fetal human brain cells into embryonic rats
342. Engraftable human neural stem cells respond to developmental cues, replace neurons, and express foreign genes
343. Regeneration in the CNS: Optimism amounts
344. Regeneration in adult central nervous system: Experimental repair strategies
345. New potential for human embryonic stem cells
346. Neural stem-like cells: Developmental lessons with therapeutic potential
347. Apoptosis and its role in human disease
348. Apoptosis in the failing human heart
349. Apoptosis in the pathogenesis and treatment of disease
350. A matter of life and cell death
351. Apoptosis induced in mammalian cells by small peptides that functionally antagonize the Rb-regulated E2F transcription factor
352. Coming to terms with death: Apoptosis in cancer and immune development
353. T-cell apoptosis in autoimmune diseases: Termination of inflammation in the nervous system and other sites with specialized immunedefense mechanisms
354. Thymocyte apoptosis. A model of programmed cell death
355. Atm selectively regulates distinct p53-dependet cell-cycle check-point and apoptotic pathways
356. Keeping neurons alive: The molecular control of apoptosis (Part I)
357. Keeping neurons alive: The molecular control of apoptosis (Part II)
358. Genetic control of programmed cell death in Drosophila
359. Programmed cell death, apoptosis and killer genes
360. Mechanisms and genes of cellular suicide
361. Death receptors: Signaling and modulation
362. Caenorhabditis elegans gene ced-9 protects cells from programmed cell death
363. Mitochondria and apoptosis
364. The Bcl-2 family of proteins, and the regulation of neuronal survival
365. Double identity for proteins of the Bcl-2 family
366. Bcl-2 and Bax function independently to regulate cell death
367. Mitochondrial control of apoptosis
368. Caspases: Enemies within
369. Caspases: Killer proteins
370. Caspases and caspase inhibitors
371. The domains of death: Evolution of the apoptosis machinery
372. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC
373. The Bcl-2 protein family: Arbiters of ceil survival Science
374. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis
375. Evolution of senescence: Cellular aging, apoptosis, immune surveillance and tumor development
376. A capase-activated Dnase that degrades DNA during apoptosis, and its inhibitor ICAD
377. Acinus is a caspase-3-activated protein required for apoptotic chromatin condensation
378. Programmed cell death in cerebral ischemia. Therapeutic implications
379. Neuronal apoptosis in acute necrotic insults: Why is this subject such a mess?
380. Examination of the interactions of the amyloid precursor protein carboxyl terminus to intracellular protein: Possible role in apoptosis
381. Excitotoxicity, free radicals, necrosis, and apoptosis
382. Regulation of cell death protease caspase-9 by phosphorylation
383. Ceramide in apoptosis - Does it really matter?
384. Ceramide: An intracellular signal for apoptosis
385. Accelerated apoptosis of culture lymphocytes in Alzheimer's disease
386. Is apoptosis key in Alzheimer's disease?
387. Cold thoughts of death: The role of ICE proteases in neuronal cell death
388. ICE/CED3-like proteases as therapeutic targets for the control of inappropriate apoptosis
389. Suppression of programmed neuronal death by sustained elevation of cytoplasmic calcium
390. RGD peptides induce apoptosis by direct caspase-3 activation
391. A caspase inhibitor blocks ischaemia-induced delayed neuronal death in the gerbil
392. Protection against oxidative stress-induced neuronal cell death - A novel role for RU486
393. Conversion of Bcl-2 to a Bax-like death effector by caspases
394. Requirement of an ICE-like protease for induction of apoptosis and ceramide generation by REAPER
395. Stress-inducible responses and heat-shock proteins: New pharmacologic targets for cytoprotection
396. Caspases land on APP: One small step for apoptosis, one giant leap for amyloidosis?
397. Caspase inhibition reduces apoptosis and increases survival of nigral transplants
398. Inhibition of neointimal cell Bcl-x expression induces apoptosis and regression of vascular disease
399. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides
400. The anti-apoptotic protein ITA is essential for NGF-mediated survival of embryonic chick neurons
401. Association of genetic risk factors in Alzheimer's disease
402. Apolipoprotein E genotype allele ε4 and response to tacrine in Alzheimer's disease
403. Apolipoprotein E-4 allele predicts a positive response to tacrine in Alzheimer's disease
404. Mining the genome for drugs
405. Genetic enhancement of learning and memory in mice
406. Pharmacogenomics: Translating functional genomics into rational therapeutics
407. Genetic variation as a guide to drug development
408. Genomics and drug discovery
409. Gene therapy: Applications to the neurosciences and to neurological diseases
410. Long-term gene therapy in the CNS: Reversal of hypothalamic diabetes insipidus in the Brattleboro rat by using an adenovirus expressing arginine vasopressin
411. Protecting communities in research: Current guidelines and limits of extrapolation
412. Inflammatory thoughts about glioma gene therapy
413. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials
414. Antisense oligonucleotides: New tools for the study of brain function
415. A good antisense molecule is hard to find
416. Antisense oligonucleotides: Toward clinical trials
417. Antisense oligonucleotides: A systematic high-throughput approach to target validation and gene function determination
418. Pharmacogenomics: Will the regulators approve?
419. Adenosine receptors as potential therapeutic targets
420. Spherons as a drug target in Alzheimer's disease
421. Chemokines in the CNS: Plurifunctional mediators in diverse states
422. The synucleins: A family of proteins involved in synaptic function, plasticity, neurodegeneration and disease
423. Signal transduction as a drug-discovery platform
424. Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines